Form 4: UTHR Exec Exercises Options, Sells Shares
Insider Transaction Report
United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options and sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.
Summary
- Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp (UTHR), executed a pre-arranged Rule 10b5-1 plan on September 18, 2025.
- The transaction involved the exercise of 11,000 stock options at an exercise price of $135.42 per share.
- Concurrently, 11,000 shares of common stock were sold in multiple open market transactions.
- The sale prices ranged from $402.50 to $408.43 per share, with weighted average prices reported for various blocks of shares.
- Following these transactions, Mahon's direct beneficial ownership of common stock decreased from 47,781 shares to 36,781 shares.
- Mahon retains beneficial ownership of 55,000 derivative securities (stock options) after the reported exercise.
Sentiment
Score: 5
Explanation: The filing reports a routine, pre-planned insider transaction (option exercise and sale) which is neutral in terms of company performance or outlook.
Positives
- The executive realized significant value from stock options, indicating a substantial increase in the company's stock price since the options were granted.
- The execution of the transaction under a Rule 10b5-1 plan demonstrates adherence to best practices for insider trading compliance, reducing concerns about opportunistic selling.
Negatives
- The sale of 11,000 shares by a key executive, even if pre-planned, represents a reduction in insider ownership, which some investors might interpret as a lack of conviction, though this is often a routine part of executive compensation and liquidity management.
Future Outlook
N/A
Industry Context
N/A
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy | The transaction was executed pursuant to a pre-arranged Rule 10b5-1 plan, which allows insiders to set up a predetermined schedule for buying or selling company stock to avoid accusations of trading on material non-public information. | December 24, 2024 | Enhances transparency and compliance with insider trading regulations, demonstrating a commitment to ethical conduct and reducing potential for market manipulation concerns. |
Stakeholder Impact
- Minor impact on shareholders due to routine insider selling, which is a common occurrence and often pre-scheduled under a 10b5-1 plan, indicating it is not based on new material information.
Key Dates
| Date | Description |
|---|---|
| 03/15/2023 | Date stock options became exercisable. |
| 12/24/2024 | Date the Rule 10b5-1 plan was entered into by the reporting person. |
| 09/18/2025 | Date of the reported stock option exercise and subsequent sale transactions. |
| 03/15/2027 | Expiration date of the stock options. |
Keywords
United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, Paul A. Mahon, 10b5-1 Plan, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.